A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Healthy Participants

Treatments: Drug: BMS-986165 Tablet formulation 1; Drug: BMS-986165 Tablet formulation 2

Study type: Interventional

Funder types: Industry

Identifiers

NCT04305899

IM011-113

Details and patient eligibility

About

The purpose of this study is to compare the taste, and the levels in blood plasma of different tablet formulations of BMS-986165 when taken by healthy adults.

Enrollment: 40 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations in the opinion of the investigator
• Women and men must agree to follow specific methods of contraception, if applicable

Exclusion Criteria:

• Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of/or active liver disease
• Inability to tolerate oral medication
• History of allergy to BMS-986165 or related compounds

Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

40 participants in 10 patient groups

Treatment Group 1

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1

Treatment Group 2

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1

Treatment Group 3

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1

Treatment Group 4

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1

Treatment Group 5

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1

Treatment Group 6

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1

Treatment Group 7

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1

Treatment Group 8

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1

Treatment Group 9

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1

Treatment Group 10

Experimental group

Treatment:

Drug: BMS-986165 Tablet formulation 2

Drug: BMS-986165 Tablet formulation 1